-
$250 million (USD) plant will help produce transformational cell and gene therapies on a global scale
-
Creating readiness for first production runs of potential commercial launches, including bemdaneprocel (BRT-DA01), BlueRock Therapeutics’ investigational cell therapy for Parkinson’s disease as well as product supply for late-stage clinical trials
-
New plant helps break industry-wide bottleneck in manufacturing capacity for regenerative medicines
-
100,000 sq. ft. building advances Bayer’s sustainability efforts – first fully electric manufacturing plant in Bayer’s global pharmaceutical manufacturing network
Chinese Patent Granted for CytoMed Therapeutics’ Licensed iPSC-Based Technology
SINGAPORE — CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced that its exclusively licensed induced pluripotent stem cell (iPSC)-based technology has been granted a patent by the China National Intellectual Property Administration (CNIPA). [Read more…]
When a Network Matters! Functional iPSC-derived Endothelial Cells Finally Arrive
Authored By: Aristotle Kayafas, Trailhead Biosystems Inc.
60,000 miles of blood vessels run all throughout the average human body (Cleveland Clinic, 2022). Mostly tiny arteries and veins, they carry life-giving blood to every part of the body, enough to make the 5800-mile round trip between New York and San Francisco close to ten times. [Read more…]
QHP Capital Acquires Applied StemCell
Strategic Financial Sponsor to Support Continued Growth and Market Expansion
October 9, 2023, Raleigh, NC, and Milpitas, CA — QHP Capital (“QHP”), today announced its acquisition of Applied StemCell, Inc. (“ASC” or the “Company”), a leading cell and gene therapy CRO/CDMO focused on supporting the research community and biotechnology industry in developing and manufacturing cell and gene products. [Read more…]
NeuroSense’s PrimeC Shows Compelling Results for ALS Survival in Novel iPSC Model
Key Points:
Groundbreaking study utilized iPSCs derived from blood samples of ALS patients to evaluate the survival rate of induced motor neurons when treated with NeuroSense’s product candidate, PrimeC.
In collaboration with the University of Southern California’s Ichida Stem Cell Lab, PrimeC significantly increased the survival rate of induced motor neurons in an in vitro study iPSCs generated from people living with ALS.
In a groundbreaking collaborative effort, NeuroSense Therapeutics Ltd. announced the results of a recent study that could be life-changing for those suffering from amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disease. The study, conducted by Dr. Justin Ichida at the University of Southern California’s Stem Cell Ichida Lab, has shown that NeuroSense’s PrimeC significantly increased the survival rate of induced motor neurons in an innovative in vitro model using induced pluripotent stem cells (iPSCs) derived from ALS patients. This discovery has the potential to revolutionize ALS treatment and bring hope to those affected by this debilitating disease. [Read more…]
- « Previous Page
- 1
- …
- 112
- 113
- 114
- 115
- 116
- …
- 336
- Next Page »